Ionis Pharmaceuticals (IONS) Stock Price

Ionis Pharmaceuticals Price

NASDAQ·CLOSED
59.74USD+0.98 (+1.65 %)
Market closed

Over the last 19 years Ionis Pharmaceuticals grew revenue by 24.4% annually, reaching 944.00 M USD. Earnings per share have grown at 2.1% per year over the last 10 years. For Ionis Pharmaceuticals, the net margin of -40.4% is down versus -3.5% a few years ago. The consensus 12-month price target for Ionis Pharmaceuticals is 96.90 USD, about 62.2% above where the stock trades today. Of 29 analysts, 22 rate the stock a buy — an overall Buy consensus. The stock trades about 42% above its 52-week low.

Ionis Pharmaceuticals stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Ionis Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ionis Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ionis Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ionis Pharmaceuticals Stock Price History
DateIonis Pharmaceuticals Price
8/21/202659.74 USD
8/20/202658.76 USD
8/19/202660.28 USD
8/18/202659.02 USD
8/14/202657.24 USD
8/13/202655.87 USD
8/12/202656.53 USD
8/11/202655.42 USD
8/10/202657.42 USD
8/7/202656.56 USD
8/6/202654.49 USD
8/5/202654.14 USD
8/4/202654.71 USD
8/3/202654.49 USD
7/31/202651.77 USD
7/30/202653.28 USD
7/29/202655.22 USD
7/27/202656.50 USD
7/23/202655.87 USD
7/22/202654.01 USD
7/21/202653.39 USD
7/20/202652.95 USD
7/17/202654.39 USD
7/16/202654.65 USD
7/15/202654.73 USD
7/14/202654.93 USD
7/13/202656.35 USD
7/10/202658.25 USD
7/9/202664.27 USD
7/8/202685.76 USD
7/7/202686.33 USD
7/6/202683.53 USD
7/2/202681.80 USD
7/1/202679.19 USD
6/30/202679.29 USD
6/29/202680.56 USD
6/26/202681.18 USD
6/25/202678.34 USD
6/24/202676.52 USD
6/23/202675.99 USD
6/22/202674.69 USD
6/18/202674.09 USD
6/17/202674.46 USD
6/16/202672.35 USD
6/15/202673.35 USD
6/12/202673.40 USD
6/11/202673.82 USD
6/10/202674.24 USD
6/9/202674.58 USD
6/8/202673.54 USD
6/5/202675.15 USD
6/4/202675.53 USD
6/3/202673.15 USD
6/2/202673.18 USD
6/1/202675.17 USD
5/29/202677.09 USD
5/28/202677.07 USD
5/27/202676.89 USD
5/26/202675.99 USD
5/22/202675.48 USD
5/21/202675.05 USD
5/20/202674.79 USD
5/19/202673.84 USD
5/18/202672.52 USD
5/15/202674.23 USD
5/14/202675.68 USD
5/13/202677.60 USD
5/12/202675.83 USD
5/11/202675.38 USD
5/8/202675.71 USD
5/7/202676.02 USD
5/6/202676.85 USD
5/5/202675.25 USD
5/4/202675.45 USD
5/1/202675.28 USD
4/30/202674.76 USD
4/29/202674.83 USD
4/28/202671.78 USD
4/27/202672.23 USD
4/24/202673.27 USD
4/23/202674.09 USD
4/22/202674.83 USD
4/21/202674.78 USD
4/20/202674.87 USD
4/17/202675.71 USD
4/16/202675.26 USD
4/15/202676.82 USD
4/14/202676.76 USD
4/13/202674.95 USD
4/10/202675.17 USD
4/9/202676.43 USD
4/8/202674.98 USD
4/7/202673.89 USD
4/6/202674.33 USD
4/2/202674.79 USD
4/1/202675.13 USD
3/31/202675.09 USD
3/30/202672.52 USD
3/27/202672.15 USD
3/26/202674.24 USD
3/25/202672.70 USD
3/24/202669.68 USD
3/23/202670.79 USD
3/20/202670.99 USD
3/19/202671.32 USD
3/18/202671.67 USD
3/17/202672.33 USD
3/16/202672.34 USD
3/13/202671.19 USD
3/12/202672.34 USD
3/11/202674.79 USD
3/10/202675.66 USD
3/9/202675.36 USD
3/6/202674.04 USD
3/5/202675.16 USD
3/4/202679.45 USD
3/3/202678.66 USD
3/2/202681.96 USD
2/27/202681.15 USD
2/26/202680.60 USD
2/25/202680.93 USD
2/24/202685.45 USD
2/23/202684.60 USD
2/20/202683.15 USD
2/19/202683.15 USD
2/18/202682.22 USD
2/17/202681.36 USD
2/13/202680.60 USD
2/12/202681.78 USD
2/11/202684.35 USD
2/10/202684.29 USD
2/9/202684.79 USD
2/6/202686.50 USD
2/5/202683.48 USD
2/4/202684.99 USD
2/3/202684.59 USD
2/2/202683.07 USD
1/30/202682.67 USD
1/29/202683.88 USD
1/28/202681.92 USD
1/27/202682.14 USD
1/26/202681.00 USD
1/23/202680.29 USD
1/22/202681.79 USD
1/21/202679.44 USD
1/20/202677.53 USD
1/16/202676.33 USD
1/15/202677.21 USD
1/14/202678.87 USD
1/13/202679.48 USD
1/12/202681.66 USD
1/9/202680.30 USD
1/8/202681.54 USD
1/7/202683.17 USD
1/6/202681.49 USD
1/5/202678.53 USD
1/2/202679.67 USD
12/31/202579.11 USD
12/30/202578.97 USD
12/29/202579.98 USD
12/26/202579.93 USD
12/24/202580.65 USD
12/23/202580.33 USD
12/22/202581.34 USD
12/19/202579.57 USD
12/18/202577.63 USD
12/17/202577.08 USD
12/16/202578.37 USD
12/15/202579.76 USD
12/12/202580.82 USD
12/11/202579.14 USD
12/10/202578.63 USD
12/9/202578.86 USD
12/8/202581.51 USD
12/5/202581.68 USD
12/4/202581.81 USD
12/3/202581.84 USD
12/2/202581.31 USD
12/1/202581.99 USD
11/28/202582.73 USD
11/26/202582.70 USD
11/25/202580.93 USD
11/24/202578.52 USD
11/21/202576.09 USD
11/20/202573.12 USD
11/19/202574.00 USD
11/18/202574.50 USD
11/17/202573.26 USD
11/14/202571.55 USD
11/13/202569.84 USD
11/12/202572.67 USD
11/11/202572.45 USD
11/10/202569.54 USD
11/7/202573.55 USD
11/6/202574.10 USD
11/5/202574.68 USD
11/4/202572.88 USD
11/3/202573.65 USD
10/31/202574.30 USD
10/30/202574.17 USD
10/29/202571.88 USD
10/28/202573.57 USD
10/27/202572.99 USD
10/24/202570.86 USD
10/23/202571.50 USD
10/22/202571.50 USD
10/21/202571.64 USD
10/20/202573.55 USD
10/17/202573.09 USD
10/16/202573.07 USD
10/15/202572.39 USD
10/14/202571.37 USD
10/13/202570.59 USD
10/10/202569.97 USD
10/9/202570.27 USD
10/8/202569.96 USD
10/7/202568.94 USD
10/6/202569.02 USD
10/3/202569.15 USD
10/2/202568.40 USD
10/1/202565.80 USD
9/30/202565.42 USD
9/29/202564.15 USD
9/26/202564.09 USD
9/25/202562.97 USD
9/24/202563.94 USD
9/23/202562.57 USD
9/22/202561.36 USD
9/19/202561.01 USD
9/18/202561.74 USD
9/17/202561.17 USD
9/16/202561.32 USD
9/15/202561.10 USD
9/12/202563.16 USD
9/11/202564.04 USD
9/10/202564.00 USD
9/9/202564.40 USD
9/8/202561.00 USD
9/5/202561.23 USD
9/4/202559.35 USD
9/3/202560.49 USD
9/2/202557.49 USD
8/29/202542.64 USD
8/28/202542.62 USD
8/27/202542.75 USD
8/26/202542.17 USD
Access this data via the Eulerpool API
Get Free API Key

Ionis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
787.65 M USD
-353.73 M USD
-366.29 M USD
Jan 1, 2024
705.14 M USD
-475.08 M USD
-453.90 M USD
Jan 1, 2025
944.00 M USD
-382.00 M USD
-381.00 M USD
Jan 1, 2026 (e)
914.06 M USD
-300.18 M USD
-585.02 M USD
Jan 1, 2027 (e)
1.38 B USD
-453.19 M USD
-309.12 M USD
Jan 1, 2028 (e)
1.98 B USD
-650.56 M USD
29.77 M USD
Jan 1, 2029 (e)
2.54 B USD
-833.26 M USD
415.73 M USD
Jan 1, 2030 (e)
3.25 B USD
-1.07 B USD
892.29 M USD

Ionis Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 2:02 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.280.350.510.601.120.730.810.590.790.710.940.911.381.982.543.25
32.2422.2648.5516.5487.48-35.0811.11-27.5334.07-10.4233.90-3.1850.8843.6528.0727.91
-13.430.58100.0099.6799.6498.3598.6497.6198.8698.3098.3198.3198.3198.3198.3198.31
-0.04–0.510.601.120.720.800.570.780.690.930.901.361.952.493.19
-0.08-0.050.03-0.030.37-0.17-0.03-0.41-0.35-0.48-0.38-0.30-0.45-0.65-0.83-1.07
-26.50-13.296.03-5.1832.59-23.59-3.70-69.85-44.85-67.38-40.47-32.82-32.85-32.81-32.83-32.82
-88.00-86.00–273.00294.00-487.00-28.00-269.00-366.00-453.00-381.00-585.00-309.0029.00415.00892.00
131.58-2.27––7.69-265.65-94.25860.7136.0623.77-15.8953.54-47.18-109.391,331.03114.94
120.19123.95126.86149.86153.00140.00160.00142.00145.54158.00162.00162.00162.00162.00162.00162.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ionis Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ionis Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ionis Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ionis Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ionis Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ionis Pharmaceuticals stock margins

The Ionis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ionis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ionis Pharmaceuticals.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
98.66 %
-3.72 %
-3.53 %
Jan 1, 2022
97.60 %
-69.84 %
-45.92 %
Jan 1, 2023
98.84 %
-44.91 %
-46.50 %
Jan 1, 2024
98.41 %
-67.37 %
-64.37 %
Jan 1, 2025
98.31 %
-40.47 %
-40.36 %
Jan 1, 2026 (e)
98.31 %
-32.84 %
-64.00 %
Jan 1, 2027 (e)
98.31 %
-32.84 %
-22.40 %
Jan 1, 2028 (e)
98.31 %
-32.84 %
1.50 %

Ionis Pharmaceuticals Stock Revenue, EBIT, Earnings per Share

The Ionis Pharmaceuticals earnings per share therefore indicates how much revenue Ionis Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.07 USD
-0.19 USD
-0.18 USD
Jan 1, 2022
4.14 USD
-2.89 USD
-1.90 USD
Jan 1, 2023
5.41 USD
-2.43 USD
-2.52 USD
Jan 1, 2024
4.46 USD
-3.01 USD
-2.87 USD
Jan 1, 2025
5.83 USD
-2.36 USD
-2.35 USD
Jan 1, 2026 (e)
5.71 USD
-1.85 USD
-3.66 USD
Jan 1, 2027 (e)
8.62 USD
-2.80 USD
-1.93 USD
Jan 1, 2028 (e)
12.38 USD
-4.02 USD
0.19 USD

Ionis Pharmaceuticals business model & stock analysis

Ionis Pharmaceuticals is a biotechnology company specializing in the development and marketing of RNA-based therapeutics for the treatment of various diseases. The company was founded in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals SWOT Analysis

Strengths

Ionis Pharmaceuticals Inc. benefits from several strengths that contribute to its success in the pharmaceutical industry. These include:

  • Strong Research and Development (R&D) capabilities, with a focus on innovative drug discovery and development.
  • Extensive intellectual property portfolio, providing Ionis Pharmaceuticals with a competitive advantage and protection for its novel therapies.
  • Collaborative partnerships with various pharmaceutical companies, enabling Ionis to leverage its technology and expand its market reach.
  • Proven track record of successful drug approvals and commercialization, demonstrating the company's ability to deliver effective treatments to patients.

Weaknesses

Despite its strengths, Ionis Pharmaceuticals Inc. also faces certain weaknesses that may hinder its growth and performance. These include:

  • Reliance on a limited number of key partnerships for revenue generation, making Ionis vulnerable to the uncertainties and decisions of its partners.
  • High research and development costs, which can strain the company's financial resources and profitability.
  • Limited international presence and dependence on the U.S. market, exposing Ionis to geopolitical and regulatory risks.

Opportunities

Ionis Pharmaceuticals Inc. can capitalize on various opportunities to further enhance its market position and growth prospects. These include:

  • Increasing demand for innovative therapies in areas of high unmet medical needs, such as rare diseases and genetic disorders.
  • Expanding partnerships with pharmaceutical companies to access additional resources, expertise, and funding for research and development.
  • Growing global healthcare expenditure, creating opportunities for market expansion and revenue growth.
  • Rapid advancements in genomics and personalized medicine, aligning with Ionis' expertise in antisense technology.

Threats

Ionis Pharmaceuticals Inc. faces several threats that could impact its business operations and future prospects. These threats include:

  • Intense competition from both established pharmaceutical companies and emerging biotech firms, increasing pressure on market share and pricing.
  • Stringent regulatory requirements and lengthy approval processes, leading to delays and uncertainties in bringing new drugs to market.
  • Risks associated with potential adverse events and safety concerns related to Ionis' drug candidates, affecting their market acceptance and commercial viability.
  • Currency exchange rate fluctuations, especially for international operations, introducing financial volatility and impacting profitability.

Ionis Pharmaceuticals Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Ionis Pharmaceuticals Employees
Details
Date
Ionis Pharmaceuticals Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Ionis Pharmaceuticals Segments

Ionis Pharmaceuticals Revenue by Segment (1/6)

  • 3 Years

  • 5 Years

  • Max

Commercial
Research and Development Revenue Under Collaborative Agreements
Details
Date
Commercial
Revenue from research and development services performed under a collaboration agreement
Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.
Revenue from research and development services
Research and Development Revenue Under Collaborative Agreements
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
254.92 M USD
0.00 USD
0.00 USD
0.00 USD
-107.14 M USD

Ionis Pharmaceuticals Revenue by Segment (2/6)

  • 3 Years

  • 5 Years

  • Max

SPINRAZA Royalties
Details
Date
Royalty revenues from the sale of SPINRAZA (nusinersen)
SPINRAZA Royalties
ION582 is an antisense investigational medicine that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA)
IONIS-MAPT is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain, for the treatment of Alzheimer's disease
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
237.93 M USD
0.00 USD
0.00 USD

Ionis Pharmaceuticals Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • Max

Licensing and Other Royalties
Details
Date
An investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)
Licensing and Other Royalties
Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
12.00 M USD
0.00 USD

Ionis Pharmaceuticals Revenue by Segment (4/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
ION532 (formerly IONIS-AZ5-2.5Rx ), also known as AZD2373, is an investigational antisense medicine designed to reduce the production of apolipoprotein L1 (APOL1) for the treatment of APOL1-associated chronic kidney disease (CKD). ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9)
ION736, formerly known as IONIS-AZ7-2.5, is a Generation 2.5 antisense drug
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD

Ionis Pharmaceuticals Revenue by Segment (5/6)

  • 3 Years

  • 5 Years

  • Max

Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties
Details
Date
Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties
Jan 1, 2017
0.00 USD
Jan 1, 2018
240.69 M USD

Ionis Pharmaceuticals Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • Max

Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties
Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders
Details
Date
Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties
Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders
Jan 1, 2017
506.86 M USD
0.00 USD
Jan 1, 2018
0.00 USD
64.87 M USD

Ionis Pharmaceuticals Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ionis Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Ionis Pharmaceuticals annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ionis Pharmaceuticals shares outstanding

The number of shares of Ionis Pharmaceuticals was 162 M in 2025. This indicates how many shares Ionis Pharmaceuticals is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
160.00 M Stocks
Jan 1, 2022
142.00 M Stocks
Jan 1, 2023
145.54 M Stocks
Jan 1, 2024
158.00 M Stocks
Jan 1, 2025
162.00 M Stocks
Jan 1, 2026 (e)
162.00 M Stocks
Jan 1, 2027 (e)
162.00 M Stocks
Jan 1, 2028 (e)
162.00 M Stocks

Current Ionis Pharmaceuticals forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.86 % (22)
Hold
24.14 % (7)
Sell
0.00 % (0)
12M Price Target
96.90
Last Price
61.25
Currency
USD
12M Return Potential
58.20 %
LTM Return
0 %

Ionis Pharmaceuticals Analyst Rating Actions

DateFirmActionRatingReliability
8/3/2026
JP Morgan
JP Morgan
MaintainedOverweight61
7/30/2026
Wells Fargo
Wells Fargo
MaintainedOverweight53
7/30/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/21/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/16/2026
Wolfe Research
Wolfe Research
DowngradeOutperformPeer Perform–
7/13/2026
RBC Capital
RBC Capital
MaintainedOutperform48
7/10/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
7/10/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/10/2026
Citigroup
Citigroup
MaintainedBuy43
7/10/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy65

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Ionis Pharmaceuticals Earnings Calls

2025

Ionis Pharmaceuticals Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/28/2026-1.11USD-193.32 MUSD-2026 Q2
4/28/2026-0.91USD-202.14 MUSD-2026 Q1
2/17/2026-1.35USD-159.22 MUSD-2025 Q4
5/1/2024-0.98USD-159.18 MUSD-2024 Q1
2/20/2024-0.95USD-161.95 MUSD-2023 Q4
11/7/2023-0.81USD-171.97 MUSD-2023 Q3
8/7/2023-0.94USD-142.41 MUSD-2023 Q2
5/2/2023-0.81USD-156.30 MUSD-2023 Q1
2/22/2023-0.88USD-163.91 MUSD-2022 Q4
11/9/2022-0.76USD-146.05 MUSD-2022 Q3
...

EESG©

Eulerpool ESG Scorecard© for the Ionis Pharmaceuticals stock

64/100
38
Environment
99
Social
55
Governance
E

Environment

20
Scope 1 - Direct Emissions2,456
Scope 2 - Indirect emissions from purchased energy1,841
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions4,297
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees53.5
Percentage of women in management—
Percentage of Asian employees25
Share of Asian management—
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share—
Percentage of Black employees3
Black Management Share—
Percentage of white employees58
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ionis Pharmaceuticals shareholder structure

% Name
15.34694%
FMR LLC
FMR LLC
15.04412%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
13.24065%
CAPITAL WORLD INVESTORS
CAPITAL WORLD INVESTORS
11.22511%
Capital World Investors
Capital World Investors
10.25158%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.52614%
BLACKROCK, INC.
BLACKROCK, INC.
...

Ionis Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)

Free Float
98.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
35.30%
Board of Directors of MetLife, Inc., as an entity
Board of Directors of MetLife, Inc., as an entity
SEC ↗
18.50%
Fifth Third Bancorp 31-0854434
Fifth Third Bancorp 31-0854434
SEC ↗
15.10%
FMR LLC
FMR LLC
SEC ↗
15.10%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
15.10%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
12.80%
Capital World Investors
Capital World Investors
SEC ↗
12.00%
N/A
N/A
SEC ↗
11.00%
Baillie Gifford & Co (Scottish partnership)
Baillie Gifford & Co (Scottish partnership)
SEC ↗
9.30%
ZFIC, Inc.
ZFIC, Inc.
SEC ↗
9.30%
Carlene M. Ziegler
Carlene M. Ziegler
SEC ↗

Ionis Pharmaceuticals Executives and Management Board

21 members · avg. age 62 · 29 % women

BM

Dr. Brett Monia (63)

Chief Executive Officer, Director · since 2009

15.40 M USD

Management

EH

Ms. Elizabeth Hougen (63)

Chief Financial Officer, Executive Vice President - Finance

5.06 M USD
KJ

Mr. Kyle Jenne (49)

Executive Vice President, Chief Global Product Strategy Officer

4.30 M USD
JB

Mr. Joseph Baroldi (47)

Executive Vice President, Chief Business Officer

4.02 M USD
RG

Dr. Richard Geary (67)

Executive Vice President, Chief Development Officer

3.47 M USD
PO

Mr. Patrick O'Neil (51)

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

3.43 M USD
ES

Dr. Eric Swayze (58)

Executive Vice President - Research

2.56 M USD

Board of Directors

SB

Dr. Spencer Berthelsen (72)

Independent Director

1.19 M USD
MY

Mr. Michael Yang (63)

Independent Director

572,212.00 USD
JW

Mr. Joseph Wender (80)

Lead Independent Director

342,162.00 USD
JL

Dr. Joseph Loscalzo (73)

Independent Chairman of the Board

312,162.00 USD
JK

Mr. Joseph Klein (63)

Independent Director

286,162.00 USD
JH

Ms. Joan Herman (71)

Independent Director

284,162.00 USD

Ionis Pharmaceuticals Supply Chain

Ionis Pharmaceuticals Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
24 companies
#Nameβ 1YTrend
1
PTC Therapeutics
Supplier·Customer·Biotechnology·US
0.85
0.49
0.61
0.06
0.33
0.83
0.32
2
Biora Therapeutics
Supplier·Customer·US
0.93
0.70
-0.25
-0.65
-0.32
0.78
—
3
Regulus Therapeutics
Supplier·Customer·Biotechnology·US
-0.12
0.07
-0.26
-0.37
0.37
0.57
—
#Nameβ 1YTrend
1
Achaogen, Inc.
Supplier·Customer·US
0.74
0.24
-0.30
0.24
0.07
—
—
2
Praxis Precision Medicines
Supplier·Customer·Biotechnology·US
0.40
0.38
-0.59
-0.77
-0.28
—
—
3
ICON
Supplier·Life Sciences Tools & Services·IE
0.42
0.51
0.38
-0.50
-0.55
-0.78
-1.03
4
Bicycl Ther Sp ADS
Supplier·Customer·Biotechnology·GB
0.48
0.37
-0.43
-0.73
-0.76
-0.77
—
5
Thermo Fisher Scientific
Supplier·Life Sciences Tools & Services·US
0.88
0.92
0.40
-0.39
-0.57
-0.76
-0.48

Frequently asked questions about Ionis Pharmaceuticals

The main competitors of Ionis Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Biogen, and Moderna.

The business model of Ionis Pharmaceuticals Inc. focuses on developing RNA-targeted drugs to treat various diseases. By harnessing the power of antisense technology, Ionis utilizes genetic information to create specific RNA-targeted therapies that can selectively modulate gene expression, preventing or treating diseases at the molecular level. Ionis collaborates with pharmaceutical partners worldwide to advance its drug candidates through clinical development and commercialization. With its extensive pipeline and groundbreaking platform, Ionis aims to revolutionize the treatment of genetic diseases and offer hope to patients in need.

Ionis Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Ionis Pharmaceuticals Inc, formerly known as Isis Pharmaceuticals Inc, is a renowned biotechnology company headquartered in Carlsbad, California. Established in 1989, Ionis specializes in discovering and developing RNA-targeted therapeutics for various diseases. The company's innovative antisense technology allows the targeting of specific genes to treat a wide range of medical conditions. Ionis is recognized for its industry-leading pipeline of drugs, focusing on areas such as cardiovascular, metabolic, and neurological disorders. With a strong commitment to advancing healthcare through groundbreaking research and development, Ionis Pharmaceuticals Inc has emerged as a prominent player in the biotech sector, consistently striving to improve patients' lives.

Ionis Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notably, the company pioneered the development of antisense technology, a groundbreaking approach to target and modulate the production of disease-causing proteins. Ionis has successfully advanced multiple antisense therapies into clinical trials and gained regulatory approvals for several of its drugs. Additionally, the company has established numerous collaborations with leading biopharmaceutical companies, further validating its innovative drug discovery platform. Ionis Pharmaceuticals Inc continues to make strides in the field of RNA-targeted therapeutics, aiming to improve the lives of patients affected by various diseases.

Ionis Pharmaceuticals Inc is primarily present in the United States.

Ionis Pharmaceuticals Inc is a renowned biopharmaceutical company known for its commitment to scientific innovation and patient-centric solutions. The company's core values revolve around excellence, integrity, and collaboration. Ionis focuses on developing transformative RNA-targeted medicines to address a wide range of diseases with high unmet medical needs. With a strong corporate philosophy centered on rigorous scientific research, Ionis prioritizes the advancement of therapeutic solutions that improve patients' lives. Ionis Pharmaceuticals Inc's dedication to pioneering therapies and strategic partnerships underscores its mission to deliver novel treatments and drive positive healthcare outcomes.

Analysts currently set an average price target of 92.16 USD for the Ionis Pharmaceuticals stock (median: 96.90 USD), implying +50.5 % versus the latest price. The consensus is based on 29 analyst ratings.

Ionis Pharmaceuticals Analyst Price Targets 2026

29 analysts currently rate the Ionis Pharmaceuticals stock: 22 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Ionis Pharmaceuticals to generate revenue of 914.06 M USD and earnings per share of -3.61 USD.

Ionis Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Ionis Pharmaceuticals share trades at 51.21 EUR (59.74 USD).

The Ionis Pharmaceuticals share (IONS) is listed on 7 stock exchanges, including: NASDAQ (IONS), Frankfurt (ISI.F), München (ISI.MU), Düsseldorf (ISI.DU), London (0JDI.L), London (0JDI.L), SIX (Zürich) (IONS.SW).

Ionis Pharmaceuticals Inc is a leading company in the field of RNA-based therapeutics. Since its founding in 1989, the company has been working to develop and bring to market innovative and effective therapies for numerous diseases. Today, the company employs over 800 people and is headquartered in Carlsbad, California. The business model of Ionis Pharmaceuticals is based on the development and commercialization of RNA-based therapeutics. These are drugs that are made based on ribonucleic acids (RNA). RNA is an important component of cells and is needed for the translation of genetic information into proteins. In the case of diseases, a disrupted RNA metabolism can lead to severe illnesses. Ionis Pharmaceuticals focuses on this aspect in the development of therapeutics and uses RNA to specifically intervene in disease mechanisms and correct them. The company has developed a broad portfolio of therapeutics. One of the most successful products is Spinraza, a medication for the treatment of spinal muscular atrophy (SMA), a hereditary disease of the motor nervous system. Spinraza is the first approved RNA-based therapeutic and has enabled a significant breakthrough in the development of this technology. Other products that the company has in its pipeline target the treatment of diseases such as diabetes, cancer, Alzheimer's, and other neurological disorders. The business model of Ionis Pharmaceuticals includes various divisions. In addition to the development of RNA-based therapeutics, the company also conducts research and development in the field of antisense technology. This involves the use of short nucleotide sequences to reduce protein expression. Unlike RNA therapy, antisense technology utilizes DNA. Ionis Pharmaceuticals is a pioneer in this field and has already developed numerous drugs based on this technology. Another important area for the company is the licensing and commercialization of therapeutics to partner companies. Ionis Pharmaceuticals has entered into a variety of collaborations with major pharmaceutical companies such as Roche, GlaxoSmithKline, and AstraZeneca. In these partnerships, the company is responsible for the development and clinical testing of the therapeutics, while the partners are responsible for the production, marketing, and distribution of the products. This allows Ionis Pharmaceuticals to leverage its expertise in RNA technology while benefiting from the distribution networks and experiences of its partner companies. Overall, the business model of Ionis Pharmaceuticals is positioned in a promising and rapidly growing market. The use of RNA and antisense technologies opens up completely new possibilities for the development of effective therapeutics for numerous diseases. With a broad portfolio of already approved and in-development drugs, as well as a strong partnership strategy, Ionis Pharmaceuticals is well-positioned to continue operating successfully in this field.

The expected revenue of Ionis Pharmaceuticals is 914.06 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Ionis Pharmaceuticals is -585.02 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Ionis Pharmaceuticals is currently -16.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ionis Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Ionis Pharmaceuticals is currently 10.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ionis Pharmaceuticals stock.

The Eulerpool Quality Score for Ionis Pharmaceuticals is 3/10.

The ISIN of Ionis Pharmaceuticals is US4622221004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Ionis Pharmaceuticals is A2ACMZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Ionis Pharmaceuticals is IONS. The ticker symbol is used to trade Ionis Pharmaceuticals shares on the stock exchange.

Ionis Pharmaceuticals paid dividends every year for the past 0 years.

Ionis Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Ionis Pharmaceuticals are distributed in USD.

All fundamentals and in-depth analysis of Ionis Pharmaceuticals

Our stock analysis for Ionis Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ionis Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Revenue→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Net Income→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals P/E→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals P/S→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals EBIT→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Dividend→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Directors Dealings→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Stocks→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Market capitalization→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Debt→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Liabilities→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Equity→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals AAQS→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Employees→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals ROE→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals ROA→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals ROCE→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals News→
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals Analyst Price Targets→

Health Stocks

Iovance BiotherapeuticsIon Beam ApplicationsIPCA LaboratoriesIOL Chemicals and PharmaceuticalsIpsenIO BiotechIQVIA HoldingsInyxIRadimedINVO FertilityiRay GroupInvivydAll Stocks A–Z →